Fibromyalgia is currently diagnosed under the 2016 research criteria, a combination of the 2010 and 2011 criteria revisions. The current guidelines have led to ongoing misdiagnosis issues dating back to the criteria initially established by the 1990 American College of Rheumatology (ACR). Given the extensive revisions to the diagnostic criteria in 2016, instances of over-and under-diagnosing as well as measurement errors corresponding to the different diagnostic criteria utilized, the current study sought to investigate changes in the incidence of fibromyalgia diagnoses and the associations between fibromyalgia diagnosis and relevant comorbidities and somatic symptoms of interest.

To investigate the awareness, implementation, and factors influencing physical activity (PA) engagement among Chinese patients with radiographic axial spondyloarthritis (r-axSpA), and their relationships with disease status.

Radiographic erosions of hands and feet are a hallmark of rheumatoid arthritis(RA) and treatment aims to prevent radiographic progression. In the at-risk phase of clinically suspect arthralgia(CSA) erosions on radiographs are rare, but can be visible on MRI which is a more sensitive imaging technique. However, the value of these MRI-erosions and especially the relation with radiographic erosions is unknown. Therefore, we aimed to study if MRI-detected erosions in CSA 1)correspond with simultaneous radiographic erosions and 2)associate with local radiographic progression.

Sleep disturbances significantly impact Behçet's Syndrome (BS) patients' quality of life. Defining the correlates of BS patients' sleep disturbances is needed to improve their management and, in turn, BS patients' quality of life. In this study, we explored fibromyalgia, disease activity, and glucocorticoid exposure as possible predictors of sleep and circadian rhythm parameters in a cohort of BS patients.

To determine the efficacy, safety, and pharmacodynamics of belumosudil in patients with diffuse cutaneous systemic sclerosis (dcSSc) treated with background immunosuppressive therapies.

Osteoarthritis (OA), a prevalent and disabling condition, significantly burdens individuals and healthcare systems worldwide. It is characterized by joint pain, stiffness, and structural changes in cartilage, bone, and synovium. The clinical manifestations of OA vary widely, reflecting complex interactions among genetic, metabolic, biomechanical, and environmental factors. Despite progress in identifying OA clinical phenotypes, inconsistent terminology, including "phenotypes," "subtypes," and "subgroups," hinders effective communication and research translation. This review aims to synthesize existing literature on clinical OA phenotypes, terminology, and definitions and propose a research agenda.

To determine the efficacy of belimumab on mucocutaneous manifestations of systemic lupus erythematosus (SLE) in a large integrative analysis.

Inclusion body myositis (IBM) is characterized by slowly progressive muscle weakness making it challenging to detect weakness changes during a clinical trial. Trial participants receiving placebo may behave differently than in natural history studies. We aimed to quantify the decline in muscle strength and IBM functional rating scale (IBMFRS) of IBM patients receiving placebo during clinical trials.

Giant cell arteritis (GCA) is a systemic vasculitis of large- and medium-sized arteries characterized by granulomatous inflammation and vascular remodelling. Although fibroblasts are the predominant cell type in the adventitia, their role in GCA pathogenesis is largely unknown. This study aimed to investigate the distribution of fibroblast subtypes in relation to vascular remodeling in GCA.

Sleep disturbance is a key symptom of fibromyalgia and a risk factor for chronic widespread pain. This systematic review and meta-analysis aims to assess the effectiveness of pharmacological treatments and cognitive behavioural therapy (CBT) in improving sleep quality in fibromyalgia patients.

Osteoarthritis (OA) is a chronic joint disease that has long been considered a simple wear-and-tear condition. Over the past decade, research has revealed that various inflammatory features of OA, such as low-grade peripheral inflammation and synovitis, contribute substantially to the pathophysiology of the disease. Technological advances in the past 5 years have revealed a large diversity of innate and adaptive immune cells in the joints, particularly in the synovium and infrapatellar fat pad. Notably, the presence of synovial lymphoid structures, circulating autoantibodies and alterations in memory T cell and B cell populations have been documented in OA. These data indicate a potential contribution of self-reactivity to the disease pathogenesis, blurring the often narrow and inaccurate line between chronic inflammatory and autoimmune diseases. The diverse immune changes associated with OA pathogenesis can vary across disease phenotypes, and a better characterization of their underlying molecular endotypes will be key to stratifying patients, designing novel therapeutic approaches and ultimately ameliorating treatment allocation. Furthermore, examining both articular and systemic alterations, including changes in the gut-joint axis and microbial dysbiosis, could open up novel avenues for OA management.

Timely, high-quality care is critical to rheumatoid arthritis (RA) management. In Alberta, thousands of individuals with RA are waiting for care due to the resource-intensive nature of lifelong follow-ups and rheumatologist shortages. With 20-50% of routine follow-ups not leading to treatment changes or raising new concerns, many appointments may be avoidable if care were restructured. Patient-initiated models extend rheumatologist follow-up intervals beyond 12 months where appropriate, which can reduce inefficiencies and improve care access. To address provincial RA care challenges, we co-developed a theory of change (TOC) for patient-initiated follow-up care.

Psoriatic arthritis (PsA) is anatomically much more heterogeneous than rheumatoid arthritis, as, beyond synovitis, it often also involves enthesitis, peritendinitis, tenosynovitis, osteitis and periostitis. This heterogeneity currently precludes a gold standard for objectively defining resolution of inflammation following treatment, with enthesitis posing a particular challenge. Despite these difficulties, we apply lessons learned from rheumatoid arthritis to describe how patients with PsA and an inadequate response to therapy can be designated within two patient subgroups, characterized by persistent inflammatory PsA (PIPsA) and non-inflammatory PsA (NIPsA), respectively. The NIPsA phenotype is defined by the lack of ongoing joint inflammation, as confirmed through clinical assessment and imaging, along with normalized inflammatory marker levels. NIPsA might be associated with obesity, biomechanical-related pain, osteoarthritis, fibromyalgia, secondary post-inflammatory damage and central pain mechanisms. In this article, we frame PsA composite outcomes measures in relationship to the PIPsA and NIPsA phenotypes and propose that this approach might help to minimize unnecessary or ineffective cycling of PsA therapy in patients who acquire dominant non-inflammatory mechanisms and might also inform future trial design.

Our overall aim was to develop a smartphone app to collect photographic images of Raynaud's phenomenon (RP) attacks alongside patient reported outcome measures (PROMs). Specific objectives included assessing the feasibility of patients documenting RP attacks using mobile phones, developing image analysis methods to document colour change, and comparing photographic parameters to 'non-imaging' app and paper diary parameters.